invex wanted a face to face meeting and the FDA neurology have promised written response only. the significance unclear, but generally interpreted as another setback.
the FDA ophthalmology sank Invex’s hopes of 1 trial with an ophthalmology endpoint, so the market is guessing that Invex won’t have much luck with getting 1 trial with the fda neurology.
and as we’ve seen with the ASX. They prefer the FDA rather than the EMA, seeing it as traditionally the largest market despite Invex insisting that there’s a larger population to treat in the EU.
- Forums
- ASX - By Stock
- IXC
- Ann: Invex Granted Type C Meeting with FDA
Ann: Invex Granted Type C Meeting with FDA, page-49
-
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
|
|||||
Last
6.0¢ |
Change
-0.007(10.5%) |
Mkt cap ! $4.509M |
Open | High | Low | Value | Volume |
6.0¢ | 6.0¢ | 6.0¢ | $3.264K | 54.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 600 | 6.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 600 | 0.060 |
1 | 15002 | 0.052 |
2 | 410000 | 0.051 |
1 | 200000 | 0.050 |
1 | 60001 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.070 | 20000 | 1 |
0.077 | 7950 | 1 |
0.078 | 20000 | 1 |
0.081 | 888 | 1 |
0.083 | 5724 | 2 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online